中国医疗前沿
中國醫療前沿
중국의료전연
CHINA HEALTHCARE INNOVATION
2013年
9期
31-32
,共2页
阿托伐他汀%不稳定型心绞痛%血脂%C反应蛋白
阿託伐他汀%不穩定型心絞痛%血脂%C反應蛋白
아탁벌타정%불은정형심교통%혈지%C반응단백
Atorvastatin%Unstable angina%Lipid%C-reactive protein
目的探讨不同剂量阿托伐他汀对不稳定型心绞痛的有效性和安全性.方法将78例不稳定性心绞痛患者随机分为两组各39例,治疗组常规治疗加上阿托伐他汀40mg/d,对照组加用阿托伐他汀20mg/d.两组均在治疗前及治疗6个月后测定血脂四项、C反应蛋白水平,观察不良心血管事件及不良反应的发生情况.结果治疗6个月后,两组血脂和C反应蛋白水平有不同程度的降低,与对照组比较,治疗组降低更显著(P<0.05);治疗组患者心血管不良事件发生率更低(P<0.05);两组不良反应事件发生率无显著差异(P>0.05).结论阿托伐他汀强化治疗能改善不稳定型心绞痛患者的预后,在权衡患者药物使用利弊后,推荐40mg/d强化治疗.
目的探討不同劑量阿託伐他汀對不穩定型心絞痛的有效性和安全性.方法將78例不穩定性心絞痛患者隨機分為兩組各39例,治療組常規治療加上阿託伐他汀40mg/d,對照組加用阿託伐他汀20mg/d.兩組均在治療前及治療6箇月後測定血脂四項、C反應蛋白水平,觀察不良心血管事件及不良反應的髮生情況.結果治療6箇月後,兩組血脂和C反應蛋白水平有不同程度的降低,與對照組比較,治療組降低更顯著(P<0.05);治療組患者心血管不良事件髮生率更低(P<0.05);兩組不良反應事件髮生率無顯著差異(P>0.05).結論阿託伐他汀彊化治療能改善不穩定型心絞痛患者的預後,在權衡患者藥物使用利弊後,推薦40mg/d彊化治療.
목적탐토불동제량아탁벌타정대불은정형심교통적유효성화안전성.방법장78례불은정성심교통환자수궤분위량조각39례,치료조상규치료가상아탁벌타정40mg/d,대조조가용아탁벌타정20mg/d.량조균재치료전급치료6개월후측정혈지사항、C반응단백수평,관찰불양심혈관사건급불량반응적발생정황.결과치료6개월후,량조혈지화C반응단백수평유불동정도적강저,여대조조비교,치료조강저경현저(P<0.05);치료조환자심혈관불량사건발생솔경저(P<0.05);량조불량반응사건발생솔무현저차이(P>0.05).결론아탁벌타정강화치료능개선불은정형심교통환자적예후,재권형환자약물사용리폐후,추천40mg/d강화치료.
@@@@Objective To abserve the influenct of different doaes of atorvastatin an the prognosis of unstable angina. Methods 78 cases of patients treated with unstable angina were randomly divided into two groups. In the control groups, 39 patients accepted conventional treatments and Atorvastatin 20mg/d, while in the treatment groups 39 patients accepted conventional treatment and Atorvastatin 40mg/d. Both groups were measured before and after 180d treatment at the four lipids, CRP, and were observed of Re-angina, myocardial infarction and cardiac death and other undesirable occurrence of cardiovascular events. Results The lipid levels of two youps have varying degrees of reduction after treatment. Compared with the control group, the observation group is more obvious(P<0.05). The two groups both reduce CRP level after treatment. Compared with the control group, the effect of the abservation group is more obvious(P<0.05). With the occurrence of adverse events, the observation group decreased signiificantly compared with the control group(P<0.05). Conclusion Atorvastatin intensive treatment can improve the prognosis of patients with unstable angina and intensive treatment after weigh in patients with drug use pros and cons, recommended 40mg/d.